Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

181. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Full Text available with Trip Pro

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD.We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002-2012, from the UK Clinical Practice (...) , was not associated with an increased risk of AMI (hazard ratio (HR) 1.12, 95% CI 0.92-1.36), stroke (HR 0.87, 95% CI 0.69-1.10) or arrhythmia (HR 1.05, 95% CI 0.81-1.36), but the risk was elevated for heart failure (HR 1.16, 95% CI 1.03-1.30).Adding a second long-acting bronchodilator in the real-world-setting treatment of COPD does not increase the risk of most cardiovascular events. The modest increase for heart failure warrants further investigation.Copyright ©ERS 2017.

2017 EvidenceUpdates

182. Trimbow (beclometasone / formoterol / glycopyrronium bromide) - chronic obstructive pulmonary disease (COPD)

applied for the following indication: Trimbow is indicated for the symptomatic treatment and reduction of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD) with airflow limitation (FEV 1 0.01 threshold (N) Substance (INN/Invented Name): glycopyrronium bromide CAS-number (if available): 51186-83-5 PBT screening Result Conclusion Bioaccumulation potential- log K ow OECD 107 -1.35 Potential PBT (N) PBT-assessment Parameter Result relevant for conclusion Conclusion (...) Trimbow (beclometasone / formoterol / glycopyrronium bromide) - chronic obstructive pulmonary disease (COPD) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 18 May 2017 EMA/CHMP/289952/2017 Committee for Medicinal Products

2017 European Medicines Agency - EPARs

183. Targeted lung denervation by catheter ablation in chronic obstructive lung disease - Assessments according to §137h SGB V

) to assess targeted lung denervation (TLD) using catheter ablation for chronic obstructive pulmonary disease (COPD) according to §137h Social Code Book (SGB) V – Statutory Health Insurance. The assessment documents were transferred to IQWiG on 19 December 2016. According to the requesting hospital, TLD aims to avoid airway obstruction in patients with COPD by a permanent interception of parasympathetic nerve fibres in the area of both main bronchi, and thereby in particular to improve respiratory (...) is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. H16-01 Targeted lung denervation using catheter ablation for chronic obstructive pulmonary disease 1 Executive summary of assessment H16-01 according to §137h SGB V Version 1.0 Targeted lung denervation for COPD 30 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Targeted lung denervation using

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

184. Roflumilast for treating chronic obstructive pulmonary disease

by obstruction of the airways, breathlessness and cough. Airflow limitation becomes worse over time, with periodic acute exacerbations. The clinical expert advised that despite treatment with optimal inhaled therapy many people with severe COPD have several exacerbations each year, which is a huge burden on patients and the NHS. Exacerbations worsen a patient's health status, reduce their quality of life, accelerate decline in lung function, lead to hospitalisation and increase mortality. The committee (...) Evidence 6 4 Committee discussion 7 Clinical need of people with COPD 7 Clinical management of COPD 7 Comparators 8 Clinical effectiveness 8 Cost effectiveness 10 Pharmaceutical Price Regulation Scheme 2014 13 Summary of appraisal committee's key conclusions 13 5 Implementation 19 6 Appraisal committee members and NICE project team 20 Appraisal committee members 20 NICE project team 20 Roflumilast for treating chronic obstructive pulmonary disease (TA461) © NICE 2018. All rights reserved. Subject

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

185. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis Full Text available with Trip Pro

Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10-70 years with a history of drug-susceptible (DS)- or multidrug-resistant (...) capacity -370 mL, 95% CI -644- -97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27-18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio <0.70 (adjusted OR 2.47, 95% CI 1.01-6.03). Individuals successfully treated for TB may experience long-lasting sequelae. Interventions facilitating earlier TB treatment and management

2017 ERJ open research

186. Impact of pulmonary rehabilitation on postoperative complications in patients with lung cancer and chronic obstructive pulmonary disease Full Text available with Trip Pro

lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD).The records of 116 patients with COPD, including 51 patients who received PR, were retrospectively analyzed. Pulmonary function testing, including slow vital capacity (VC) and forced expiratory volume in one second (FEV1 ), was obtained preoperatively, after PR, and at one and six months postoperatively. The recovery rate of postoperative pulmonary function was standardized for functional loss associated (...) Impact of pulmonary rehabilitation on postoperative complications in patients with lung cancer and chronic obstructive pulmonary disease Given the extent of the surgical indications for pulmonary lobectomy in breathless patients, preoperative care and evaluation of pulmonary function are increasingly necessary. The aim of this study was to assess the contribution of preoperative pulmonary rehabilitation (PR) for reducing the incidence of postoperative pulmonary complications in non-small cell

2017 Thoracic cancer

187. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD Full Text available with Trip Pro

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease.For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium (...) /olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler. Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75% of peak incremental work rate after 6 weeks (2 h post-dose).295 and 291 patients were treated in MORACTO 1 and 2, respectively. Tiotropium/olodaterol 2.5/5 and 5/5 µg provided significant improvements in inspiratory capacity versus placebo

2017 EvidenceUpdates

188. [Procedure for lung volume reduction in severe lung emphysema]

publication URL Indexing Status Subject indexing assigned by CRD MeSH Emphysema; Humans; Lung; Pneumonectomy; Pulmonary Emphysema Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000266 Date abstract record published 13/06/2017 Health Technology (...) [Procedure for lung volume reduction in severe lung emphysema] Verfahren zur lungenvolumenreduktion beim schweren lungenemphysem: abschlussbericht; auftrag N14-04 [Procedure for lung volume reduction in severe lung emphysema] Verfahren zur lungenvolumenreduktion beim schweren lungenemphysem: abschlussbericht; auftrag N14-04 [Procedure for lung volume reduction in severe lung emphysema] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record

2017 Health Technology Assessment (HTA) Database.

189. Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines

the use of colistin for the prophylactic treatment of adults with either non-CF bronchiectasis or patients with COPD experiencing exacerbations. Tags copd, infection control, bronchiectasis, colistin, pulmonary disease, chronic obstructive, pulmonary emphysema, respiratory, colistimethate sodium, polymyxin E, Colisticin, chronic airflow obstruction, Chronic obstructive airway disease, Chronic obstructive lung disease, Chronic obstructive pulmonary disease, chronic bronchitis, emphysema, colomycin (...) pulmonary disease experiencing exacerbations? What is the cost-effectiveness of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients with chronic obstructive pulmonary disease experiencing exacerbations? What are the evidence-based guidelines associated with the use of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients with chronic obstructive pulmonary disease experiencing exacerbations

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

190. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Full Text available with Trip Pro

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long-acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long-acting muscarinic antagonists approved (...) for treatment of patients with stable COPD.To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.We included randomised controlled trials (RCTs

2017 Cochrane

191. Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data Full Text available with Trip Pro

Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data It is often difficult to determine the cause of chronic obstructive pulmonary disease (COPD) exacerbations, and antibiotics are frequently prescribed. This study conducted an observational cost-effectiveness analysis of prescribing antibiotics for exacerbations of COPD based on routinely collected data from patient electronic health records. A cohort of 45 375 patients aged 40 years or more who (...) in the base case. The use of antibiotics for COPD exacerbations resulted in cost savings and an improvement in all outcomes analysed; i.e. GP visits, hospitalisations, community respiratory team referrals, all referrals, infections and subsequent antibiotics prescriptions were lower for the antibiotics group. Hence, the use of antibiotics was dominant over no antibiotics. The economic analysis suggests that use of antibiotics for COPD exacerbations is a cost-effective alternative to not prescribing

2017 ERJ open research

192. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Full Text available with Trip Pro

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD.To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD.In a retrospective cohort study, we used data from 14 350 patients with COPD included (...) in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012. Patients were followed up for 6 months to compare incident cardiovascular (ie, ischaemic heart disease, stroke, heart failure, peripheral vascular disease and cardiac arrhythmias

2017 EvidenceUpdates

193. Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease. Full Text available with Trip Pro

Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction due to an abnormal inflammatory response of the lungs to noxious particles or gases, for example, cigarette smoke. The pattern of care for people with moderate to very severe COPD often involves regular lengthy hospital admissions, which result in high healthcare costs and an undesirable effect on quality (...) function, or anxiety and depression.All three studies included our primary outcome - health-related quality of life (HRQoL) as measured by the Clinical COPD Questionnaire (CCQ) or St George's Respiratory Questionnaire (SGRQ). One study reported our other primary outcomes - hospital admissions and acute exacerbations. Two studies included our secondary outcome of physical activity as measured by daily step counts. One study addressed smoking by providing a narrative analysis. Only one study reported

2017 Cochrane

194. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death.To investigate the effect of home NIV plus oxygen on time to readmission or death in patients with persistent (...) hypercapnia after an acute COPD exacerbation.A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible.There were 59 patients randomized to home oxygen alone (median oxygen

2017 JAMA Controlled trial quality: predicted high

195. The population attributable fraction of occupational COPD among Danish women Full Text available with Trip Pro

The population attributable fraction of occupational COPD among Danish women The PAF of occupational COPD among Danish women http://ow.ly/CEmy308XEgl.

2017 ERJ open research

196. A qualitative study of women's experiences of living with COPD Full Text available with Trip Pro

A qualitative study of women's experiences of living with COPD To explore women's experiences of living with chronic obstructive pulmonary disease (COPD) at home.An explorative and descriptive qualitative design.A consecutive sample of nine women with COPD living at home. Data were collected in 2014 using semi-structured interviews and analysed using a qualitative content analysis.Three main themes were identified: having a good life with COPD despite limitations; predictability and confidence (...) in getting help; and the struggle to achieve a balance between insight and compliance with management of COPD. These women experienced limitations related to the traditional female role and felt unable to fulfil their own expectations. They experienced a good life despite limitations arising from adaptation and coping strategies. To feel safe, they needed to feel confident that they would receive the necessary help in case of exacerbation of their disease. To enhance compliance with COPD management

2017 Nursing open

197. Chronic obstructive pulmonary disease. (Abstract)

Chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) kills more than 3 million people worldwide every year. Despite progress in the treatment of symptoms and prevention of acute exacerbations, few advances have been made to ameliorate disease progression or affect mortality. A better understanding of the complex disease mechanisms resulting in COPD is needed. Smoking cessation programmes, increasing physical activity, and early detection and treatment (...) of comorbidities are further key components to reduce the burden of the disease. However, without a global political and economic effort to reduce tobacco use, to regulate environmental exposure, and to find alternatives to the massive use of biomass fuel, COPD will remain a major health-care problem for decades to come.Copyright © 2017 Elsevier Ltd. All rights reserved.

2017 Lancet

198. CRACKCast E074 – COPD

to Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is: “a preventable and treatable disease with some significant extra-pulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible… the airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases.” This used to include elements of reversible airflow (...) limitation (i.e. asthma) and chronic bronchitis (increased sputum for x 3 months for last 2 consecutive years, +/- airflow limitation) Don’t make the rookie mistake of mixing up COPD and emphysema: The latter is a destructive process. Classically centrilobular emphysema is a component of COPD. Alternatively, severe panacinar emphysema is associated with α1- antitrypsin deficiency, an enzyme that inhibits neutrophil elastase (ie stops your neutrophils from melting your lung parenchyma) (Big shout out

2017 CandiEM

199. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk Full Text available with Trip Pro

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect of inhaled COPD treatments on CVD outcomes and safety in patients with COPD and at heightened CVD risk.The SUMMIT (Study to Understand Mortality and MorbidITy) was a multicentre, randomised, double-blind, placebo-controlled, event-driven trial in 16 485 patients (...) , including palpitations and arrhythmias, did not differ by treatment.In patients with COPD with moderate airflow limitation and heightened CVD risk, treatment with inhaled VI, FF or their combination has an excellent safety profile and does not impact CVD outcomes.NCT01313676.© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

2017 EvidenceUpdates

200. Intermittent cortisone injection for treatment of osteoarthritis and chronic obstructive lung disease

Intermittent cortisone injection for treatment of osteoarthritis and chronic obstructive lung disease Upprepad intramuskulär injektion med kortison för att behandla artros och kroniskt obstruktiv lungsjukdom Vi använder cookies för att optimera webbplatsen på bästa sätt. Om du fortsätter innebär det att du accepterar att cookies används. Statens beredning för medicinsk och social utvärdering Upprepad intramuskulär injektion med kortison för att behandla artros och kroniskt obstruktiv (...) glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. In: Annals of the rheumatic diseases; 2010. p 503-9. Dorleijn DM, Luijsterburg PA, Reijman M, Kloppenburg M, Verhaar JA, Bindels PJ, et al. Intramuscular corticosteroid injection versus placebo effective in pain reduction in patients with hip osteoarthritis. Osteoarthritis and Cartilage 2016;24 SUPPL. 1:183-5. Eiser N, Phillips C, Wooler P, Partridge M. Comparison of oral and depot intra-muscular

2017 Swedish Council on Technology Assessement